Portal de Periódicos da CAPES

NSAIDs and stroke risk

2011; Wiley; Volume: 195; Issue: 9 Linguagem: Sueco

10.5694/mja11.11185

1326-5377

David Blacker,

S100 Proteins and Annexins

Medical Journal of AustraliaVolume 195, Issue 9 p. 488-488 Editorial NSAIDs and stroke risk David J Blacker MB BS, FRACP, Corresponding Author David J Blacker MB BS, FRACP Neurologist; and Clinical Associate Professor of Neurology [email protected] Sir Charles Gairdner Hospital, Perth, WA. University of Western Australia, Perth, WA.Correspondence: [email protected]Search for more papers by this author David J Blacker MB BS, FRACP, Corresponding Author David J Blacker MB BS, FRACP Neurologist; and Clinical Associate Professor of Neurology [email protected] Sir Charles Gairdner Hospital, Perth, WA. University of Western Australia, Perth, WA.Correspondence: [email protected]Search for more papers by this author First published: 07 November 2011 https://doi.org/10.5694/mja11.11185Citations: 2Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1O'Donnell MJ, Xavier D, Lui L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case control study. Lancet 2010; 376: 112–123. 2Caughey GE, Roughead EE, Pratt N, et al. Stroke risk and NSAIDs: an Australian population-based study. Med J Aust 2011; 195: 525–529. 3McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633–1644. 4Brott TG, Halperin JL, Abbara S, et al. Guideline on the management of patients with extracranial carotid and vertebral artery disease. Stroke 2011; 42: e464–e540. 5Chen LC, Ashcroft DM. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomised controlled trials. J Clin Pharm Ther 2006; 31: 565–576. 6Haag MD, Bos MJ, Hofman A, et al. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 2008; 168: 1219–1224. 7Chang C, Shau W, Kuo C, et al. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs. A nationwide case–crossover study. Stroke 2010; 41: 1884–1890. 8Rothwell PM. Does blood pressure variability modulate cardiovascular risk? Curr Hypertens Rep 2011; 13: 177–186. 9Chan CC, Reid CM, Aw TJ, et al. Do COX-2 inhibitors raise blood pressure more than non-selective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27: 2332–2341. Citing Literature Volume195, Issue9November 2011Pages 488-488 ReferencesRelatedInformation